Literature DB >> 17462786

Therapeutic potential for microRNAs.

Christine C Esau1, Brett P Monia.   

Abstract

MiRNAs are a conserved class of non-coding RNAs that negatively regulate gene expression post-transcriptionally. Although their biological roles are largely unknown, examples of their importance in cancer, metabolic disease, and viral infection are accumulating, suggesting that they represent a new class of drug targets in these and likely many other therapeutic areas. Antisense oligonucleotide approaches for inhibiting miRNA function and siRNA-like technologies for replacement of miRNAs are currently being explored as tools for uncovering miRNA biology and as potential therapeutic agents. The next few years should see significant progress in our understanding of miRNA biology and the advancement of the technology for therapeutic modulation of miRNA activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462786     DOI: 10.1016/j.addr.2007.03.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  60 in total

1.  High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer.

Authors:  Xiao-Guang Liu; Wang-Yu Zhu; Yan-Yan Huang; Li-Na Ma; Shi-Quan Zhou; Ye-Kai Wang; Fang Zeng; Ji-Hang Zhou; Yong-Kui Zhang
Journal:  Med Oncol       Date:  2011-04-24       Impact factor: 3.064

Review 2.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

Review 3.  New promising drug targets in cancer- and metastasis-initiating cells.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Drug Discov Today       Date:  2010-03-23       Impact factor: 7.851

4.  Biological mechanism analysis of acute renal allograft rejection: integrated of mRNA and microRNA expression profiles.

Authors:  Shi-Ming Huang; Xia Zhao; Xue-Mei Zhao; Xiao-Ying Wang; Shan-Shan Li; Yu-Hui Zhu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 5.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 6.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

Review 7.  Toll gates to periodontal host modulation and vaccine therapy.

Authors:  George Hajishengallis
Journal:  Periodontol 2000       Date:  2009       Impact factor: 7.589

Review 8.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.

Authors:  L Ouyang; Z Shi; S Zhao; F-T Wang; T-T Zhou; B Liu; J-K Bao
Journal:  Cell Prolif       Date:  2012-10-03       Impact factor: 6.831

9.  STarMir Tools for Prediction of microRNA Binding Sites.

Authors:  Shaveta Kanoria; William Rennie; Chaochun Liu; C Steven Carmack; Jun Lu; Ye Ding
Journal:  Methods Mol Biol       Date:  2016

10.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.

Authors:  Nuo Yang; Sippy Kaur; Stefano Volinia; Joel Greshock; Heini Lassus; Kosei Hasegawa; Shun Liang; Arto Leminen; Shan Deng; Lori Smith; Cameron N Johnstone; Xian-Ming Chen; Chang-Gong Liu; Qihong Huang; Dionyssios Katsaros; George Adrian Calin; Barbara L Weber; Ralf Bützow; Carlo M Croce; George Coukos; Lin Zhang
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.